Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy

Marco Colleoni, G. Viale, David Zahrieh, L. Bottiglieri, R. D. Gelber, P. Veronesi, A. Balduzzi, R. Torrisi, A. Luini, M. Intra, S. Dellapasqua, A. Cardillo, R. Ghisini, G. Peruzzotti, A. Goldhirsch

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Purpose: To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy. Materials and methods: We reviewed the pretreatment biopsies of 485 patients with locally advanced breast cancer (cT2-T4, N0-2, M0) treated with preoperative chemotherapy. The incidence of pathological complete remission (pCR) and outcome were assessed with respect to clinical and pathological findings including ER/PgR status (absent versus expressed), HER1 (absent versus expressed) and HER2 (overexpressed versus none) expression. Results: Patients with ER/PgR-absent tumors were 12.0 times [95% confidence interval (CI) 4.93-29.28] more likely to achieve a pCR (P < 0.0001). Predictors of disease-free survival (DFS) at the univariate analysis included HER1 [hazards ratio (HR) 1.6, 95% CI 1.04-2.32, P = 0.03] and HER2 (HR 1.6, 95% CI 1.08-2.38, P = 0.02) expression. A statistically significant difference in DFS was confirmed at the multivariate analysis for patients with ER/PgR-absent disease (HR 2.1, 95% CI 1.41-2.99, P = 0.0002). Conclusions: The pCR rate is higher and outcome worse for patients with ER/PgR-absent tumors. HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies.

Original languageEnglish (US)
Pages (from-to)465-472
Number of pages8
JournalAnnals of Oncology
Volume19
Issue number3
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

Progesterone
Estrogens
Drug Therapy
Confidence Intervals
Disease-Free Survival
Breast Neoplasms
Epidermal Growth Factor
Neoplasms
Multivariate Analysis
Biopsy
Incidence

Keywords

  • Breast cancer
  • Predictive factors
  • Primary chemotherapy
  • Prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Colleoni, M., Viale, G., Zahrieh, D., Bottiglieri, L., Gelber, R. D., Veronesi, P., ... Goldhirsch, A. (2008). Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy. Annals of Oncology, 19(3), 465-472. https://doi.org/10.1093/annonc/mdm509

Expression of ER, PgR, HER1, HER2, and response : A study of preoperative chemotherapy. / Colleoni, Marco; Viale, G.; Zahrieh, David; Bottiglieri, L.; Gelber, R. D.; Veronesi, P.; Balduzzi, A.; Torrisi, R.; Luini, A.; Intra, M.; Dellapasqua, S.; Cardillo, A.; Ghisini, R.; Peruzzotti, G.; Goldhirsch, A.

In: Annals of Oncology, Vol. 19, No. 3, 01.03.2008, p. 465-472.

Research output: Contribution to journalArticle

Colleoni, M, Viale, G, Zahrieh, D, Bottiglieri, L, Gelber, RD, Veronesi, P, Balduzzi, A, Torrisi, R, Luini, A, Intra, M, Dellapasqua, S, Cardillo, A, Ghisini, R, Peruzzotti, G & Goldhirsch, A 2008, 'Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy', Annals of Oncology, vol. 19, no. 3, pp. 465-472. https://doi.org/10.1093/annonc/mdm509
Colleoni, Marco ; Viale, G. ; Zahrieh, David ; Bottiglieri, L. ; Gelber, R. D. ; Veronesi, P. ; Balduzzi, A. ; Torrisi, R. ; Luini, A. ; Intra, M. ; Dellapasqua, S. ; Cardillo, A. ; Ghisini, R. ; Peruzzotti, G. ; Goldhirsch, A. / Expression of ER, PgR, HER1, HER2, and response : A study of preoperative chemotherapy. In: Annals of Oncology. 2008 ; Vol. 19, No. 3. pp. 465-472.
@article{79419e63a3e3468fa13640aacc1023b1,
title = "Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy",
abstract = "Purpose: To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy. Materials and methods: We reviewed the pretreatment biopsies of 485 patients with locally advanced breast cancer (cT2-T4, N0-2, M0) treated with preoperative chemotherapy. The incidence of pathological complete remission (pCR) and outcome were assessed with respect to clinical and pathological findings including ER/PgR status (absent versus expressed), HER1 (absent versus expressed) and HER2 (overexpressed versus none) expression. Results: Patients with ER/PgR-absent tumors were 12.0 times [95{\%} confidence interval (CI) 4.93-29.28] more likely to achieve a pCR (P < 0.0001). Predictors of disease-free survival (DFS) at the univariate analysis included HER1 [hazards ratio (HR) 1.6, 95{\%} CI 1.04-2.32, P = 0.03] and HER2 (HR 1.6, 95{\%} CI 1.08-2.38, P = 0.02) expression. A statistically significant difference in DFS was confirmed at the multivariate analysis for patients with ER/PgR-absent disease (HR 2.1, 95{\%} CI 1.41-2.99, P = 0.0002). Conclusions: The pCR rate is higher and outcome worse for patients with ER/PgR-absent tumors. HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies.",
keywords = "Breast cancer, Predictive factors, Primary chemotherapy, Prognostic factors",
author = "Marco Colleoni and G. Viale and David Zahrieh and L. Bottiglieri and Gelber, {R. D.} and P. Veronesi and A. Balduzzi and R. Torrisi and A. Luini and M. Intra and S. Dellapasqua and A. Cardillo and R. Ghisini and G. Peruzzotti and A. Goldhirsch",
year = "2008",
month = "3",
day = "1",
doi = "10.1093/annonc/mdm509",
language = "English (US)",
volume = "19",
pages = "465--472",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Expression of ER, PgR, HER1, HER2, and response

T2 - A study of preoperative chemotherapy

AU - Colleoni, Marco

AU - Viale, G.

AU - Zahrieh, David

AU - Bottiglieri, L.

AU - Gelber, R. D.

AU - Veronesi, P.

AU - Balduzzi, A.

AU - Torrisi, R.

AU - Luini, A.

AU - Intra, M.

AU - Dellapasqua, S.

AU - Cardillo, A.

AU - Ghisini, R.

AU - Peruzzotti, G.

AU - Goldhirsch, A.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Purpose: To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy. Materials and methods: We reviewed the pretreatment biopsies of 485 patients with locally advanced breast cancer (cT2-T4, N0-2, M0) treated with preoperative chemotherapy. The incidence of pathological complete remission (pCR) and outcome were assessed with respect to clinical and pathological findings including ER/PgR status (absent versus expressed), HER1 (absent versus expressed) and HER2 (overexpressed versus none) expression. Results: Patients with ER/PgR-absent tumors were 12.0 times [95% confidence interval (CI) 4.93-29.28] more likely to achieve a pCR (P < 0.0001). Predictors of disease-free survival (DFS) at the univariate analysis included HER1 [hazards ratio (HR) 1.6, 95% CI 1.04-2.32, P = 0.03] and HER2 (HR 1.6, 95% CI 1.08-2.38, P = 0.02) expression. A statistically significant difference in DFS was confirmed at the multivariate analysis for patients with ER/PgR-absent disease (HR 2.1, 95% CI 1.41-2.99, P = 0.0002). Conclusions: The pCR rate is higher and outcome worse for patients with ER/PgR-absent tumors. HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies.

AB - Purpose: To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy. Materials and methods: We reviewed the pretreatment biopsies of 485 patients with locally advanced breast cancer (cT2-T4, N0-2, M0) treated with preoperative chemotherapy. The incidence of pathological complete remission (pCR) and outcome were assessed with respect to clinical and pathological findings including ER/PgR status (absent versus expressed), HER1 (absent versus expressed) and HER2 (overexpressed versus none) expression. Results: Patients with ER/PgR-absent tumors were 12.0 times [95% confidence interval (CI) 4.93-29.28] more likely to achieve a pCR (P < 0.0001). Predictors of disease-free survival (DFS) at the univariate analysis included HER1 [hazards ratio (HR) 1.6, 95% CI 1.04-2.32, P = 0.03] and HER2 (HR 1.6, 95% CI 1.08-2.38, P = 0.02) expression. A statistically significant difference in DFS was confirmed at the multivariate analysis for patients with ER/PgR-absent disease (HR 2.1, 95% CI 1.41-2.99, P = 0.0002). Conclusions: The pCR rate is higher and outcome worse for patients with ER/PgR-absent tumors. HER1 and HER2 expression may have a prognostic role in locally advanced breast cancer and warrant further studies.

KW - Breast cancer

KW - Predictive factors

KW - Primary chemotherapy

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=40149100006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40149100006&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm509

DO - 10.1093/annonc/mdm509

M3 - Article

C2 - 17986623

AN - SCOPUS:40149100006

VL - 19

SP - 465

EP - 472

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -